

Katharina Drechsel, Constanze Radek, Carolin Kolbe, Daniela Mauer, Kristina Schweizer, Nadine Mockel-Tenbrinck, Thomas Schaser, Ian C.D. Johnston, and Andrew D.M. Kaiser
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

Introduction

Genetically engineered T cells redirected against cancer show tremendous clinical potential. However, adoptive immunotherapy still faces several challenges in the complexity associated with the current clinical manufacturing methods. Most commonly used protocols for the preparation of autologous gene-modified T cells employ lenti- or gamma-retroviral vectors to obtain a stable expression of the transgene (e.g. chimeric antigen receptors). Conventionally, the protocols comprise many (open) handling steps, are

labor intensive and are not adapted for commercial manufacturing. For lentiviral transduction and expansion of selected T cells, we recently released a highly automated manufacturing process based on the CliniMACS Prodigy® Platform, the T Cell Transduction (TCT) Process. Now we have further developed our process to include spinoculation and enable gamma-retroviral transduction within the single-use closed system. The transduction efficiency was further increased by adding the soluble transduction enhancer Vectofusin-1®.

Methods

1 Automated retroviral transduction on the CliniMACS Prodigy®

The complete process to generate genetically engineered T cells was performed in a single-platform, closed system, the CliniMACS Prodigy®, using the Tubing Set TS 520. Spinoculation was integrated as flexible programmable

activity into the existing automated TCT Process (fig. 1). Small-scale experiments were performed with the same reagents in tissue-culture plates.




Figure 1

Results

1 Spinoculation and Vectofusin-1® increase transduction efficiencies in small scale

In small-scale experiments magnetically enriched CD4⁺ and CD8⁺ T cells were activated with TransAct™ T Cell Reagent in TexMACS™ Medium supplemented with IL-2. T cells were transduced after two days in culture with gamma-retroviral vector encoding GFP with pseudotypes RD114 at MOI 2 (fig. 2A) and GALV at MOI 1 (fig. 2B); n = 6.

Cultures were washed 6 h or 24 h after transduction and analyzed on day 7 of cultivation via flow cytometry. Transduction efficiencies could be increased by adding the soluble transduction enhancer Vectofusin-1® (10 µg/mL). Best results were obtained using the spinoculation protocol (2 h centrifugation at 400xg, 32 °C).




Figure 2

2 Efficient transduction on the CliniMACS Prodigy® with gamma-retroviral vectors

The spinoculation protocol was transferred to the automated system and feasibility with gamma-retroviral vectors encoding GFP was assessed. Transduction rates of enriched CD4⁺/CD8⁺ T cells transduced on day 2 with gamma-retroviral GFP vector (GALV) could be increased by adding Vectofusin-1 to the culture prior to spinoculation at 400xg for 2 h (fig. 3A, B).

Using the condition previously optimized in small scale for RD114 with Vectofusin-1 and spinoculation also resulted in good transduction efficiencies in the CliniMACS Prodigy (fig. 3C, D). Transductions with GALV and RD114 pseudotypes performed on the CliniMACS Prodigy yielded results comparable to the respective small-scale controls (fig 3E).




Figure 3

3 Expansion and characterization of cell product

After transduction on day 2 in the CliniMACS Prodigy, the T cells stimulated with TransAct T Cell Reagent were further expanded in the CliniMACS Prodigy using the automated feeding and media exchange activities of the TCT Process (fig. 4). Vectofusin-1 did not have a negative effect on the expansion. After the automated formulation and harvest in isotonic NaCl solution, an average of 1.159x10⁹ viable cells could be generated, with an average of 5.121x10⁸ viable

transduced cells in total. For the characterization of the cell product, the blood product, the enriched fraction, the cultivated cells on day 7, and the final product were analyzed by flow cytometry for their cell composition (fig. 5A). The increase in the percentage of CD8⁺ T cells shows that the cultivation conditions favored expansion of these cells. The majority of T cells had the central memory T cell phenotype (fig. 5B).




Figure 4




Figure 5

Conclusion

- To enable gamma-retroviral transduction, spinoculation has been implemented into the T Cell Transduction Process on the CliniMACS Prodigy for automated enrichment, activation, transduction, and expansion of T cells.
- Feasibility of the generation of clinically relevant numbers of gamma-retrovirally modified T cells could be shown with the pseudotypes GALV and RD114.
- Vectofusin-1 as well as spinoculation increase transduction efficiencies and thus reduce the amount and cost of viral vector needed per manufacturing run.
- The flexibility and ease of use associated with the TCT process and the CliniMACS Prodigy Platform will enable the development of cellular therapies for the treatment of large patient groups and make economic commercial-scale manufacturing possible.

ARAT has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667980.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS® GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485. In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System. In the US, the CliniMACS Prodigy® T Cell Transduction Process is available for research use only. In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, MACS, the MACS logo, MACSQuant, TextMACS, and TransAct are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2016 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.